Palisade Bio, Inc.
PALI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.08 | 0.05 | 1.05 |
| FCF Yield | -521.87% | -18.40% | -19.48% | -8.14% |
| EV / EBITDA | 0.49 | -3.95 | -3.74 | -7.12 |
| Quality | ||||
| ROIC | -190.18% | -111.28% | -121.45% | -113.65% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.91 | 0.94 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -9.48% | 16.70% | 9.50% | -209.45% |
| Safety | ||||
| Net Debt / EBITDA | 0.65 | 0.98 | 0.79 | 0.43 |
| Interest Coverage | -1,238.25 | -871.33 | -1,209.31 | -4.89 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -1.12 |
| Cash Conversion Cycle | -134,441.67 | 216.08 | -3,844.52 | -3,200.27 |